The webinar will take place at 11am and will be repeated at 7.30pm for those who are unable to listen during the day.
Hosted by Zoetis vet Dr Wendy Talbot the session will last for approximately an hour and equates to 8 AMTRA CPD points.
Wendy will explain the current situation and recommended approaches to help slow resistance.
The webinar will conclude with a live Q&A to give everyone the opportunity to discuss any queries, concerns or common questions they hear from their customers with Wendy.
Zoetis Equine Product Manager, Penny McCann said: "Our webinars continue to be very well received.
“This one is particularly important as it explains the important new thinking around the use of anthelmintics in order to address the serious challenge of resistance.
"It’s a must for all those involved with prescribing.”
To book the 11am webinar: https://register.gotowebinar.com/register/6163460189961597967 To book the 7.30pm webinar: https://register.gotowebinar.com/register/6394015684169009164
The successful candidates, who completed their studies during 2020 and passed the examination in November, are Lucy Wilson (pictured right), from Equibreed UK, Reading, Vanessa Austin, who works at at Vets4Pets, Northampton, and Donna Johnson, the Clinical Services Manager at The Pet Vet, Barnsley.
Lucy said: “I chose to do the CVPM to cement my knowledge of how to run our practice to the best of my ability and to provide the highest level of support to my colleagues. The CVPM resources, syllabus and experience have given me a thorough understanding of my skills and areas to develop. I cannot recommend the experience highly enough.”
Chair of the VMG Certification and Training Committee, Philippa Davies, said: “The CVPM exam tests candidates’ skills in operational management, prioritising, strategy, and thinking on your feet. It’s a gruelling assessment and holders are an elite group. We are delighted to welcome Vanessa, Donna and Lucy and congratulate them on their achievement.”
For more information, visit: https://www.vetmg.com/education/cvpm/
Boehringer Ingelheim Vetmedica has launched a series of information sheets written by veterinary surgeons, nutritionists and leading riders to support its muscle building supplement for horses, Equitop Myoplast Power Pearls.
Available to download as PDFs from its website - http://www.equitop-myoplast.co.uk - this resource for horse owners covers a range of feeding topics including training the young showjumper and feeding the performance horse, older horses and horses during periods of rest and recuperation.
New video and written testimonials from performance riders and veterinary surgeons are now on the website, which also offers owners advice on healthy lean muscle growth and the benefits of Equitop Myoplast. Olympic dressage rider, Emile Faurie, international showjumpers, Ellen Whitaker and Scott Brash, and show horse producer, Katie Jerram, all endorse the product.
A client leaflet has also been launched featuring the testimonials and providing owners with information on Equitop Myoplast and an online offer of £15 off their first purchase of the supplement by downloading a voucher from the website.
Boehringer says Equitop Myoplast is packed with 18 key amino acids and is scientifically designed to support lean muscle growth, not bulk. The company says the supplement is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
Boehringer Ingelheim VetMedica has published its equine endocrine webinars online for veterinary professionals to view on demand at www.prascend.co.uk/webinars.
The webinars, which cover 'Diagnostic challenges in equine endocrine disease', presented by equine internal medicine specialist Andy Durham from the Liphook Equine Hospital, and 'A problem-based approach to equine laminitis', presented by equine internal medicine specialist Dr Catherine McGowan from the University of Liverpool, are each one hour long.
Participants will each receive CPD certificates for participation.
Virbac has launched Inflacam, a meloxicam-based NSAID for the alleviation of pain in both acute and chronic musculo-skeletal disorders in dogs and horses.
Inflacam is presented both as an oral suspension and as a chewable tablet for dogs. The suspension is available in 200ml, 100ml, 42ml and 15ml sizes with a measuring syringe provided. The tablets come in two sizes - 1 mg and 2.5 mg - and are available in packs of 100. It is available for horses as an oral suspension.
Virbac Product Manager Chris Geddes MRCVS, said: "Virbac is well known for launching innovative products in areas such as dermatology and reproduction but we also aim to support practices by offering tried and trusted practice 'standards' for everyday use. Inflacam fits this brief well - meloxicam is the most commonly-used NSAID in dogs and we are delighted to add it to our range."
For more information contact your territory manager or call Virbac on 01359 243 243.
Intervet/Schering-Plough Animal Health has reported that since launch, its diagnostic service RespCheck has identified infectious diseases in 15 per cent of all animals checked under the scheme.
Offered to qualifying practices for no charge and implemented by the Animal Health Trust (AHT), Intervet/Schering Plough set up RespCheck to help identify the cause of infectious respiratory problems in horses.
The RespCheck kit, which has been used to swab more than 700 horses since launch, consists of naso pharyngeal swabs, enabling two horses per yard or outbreak to be swabbed for a variety of diseases. These include equine influenza, equine herpesvirus, Streptococcus equi (strangles), pasteurella, rhinovirus and Streptococcus zooepidemicus. The swabs are sent to the AHT for analysis and the results returned direct to the vet.
John Dickerson from Chine House Equine Hospital in Leicestershire said: "The service is fantastic, made all the better by being completely free of charge! The benefits are two-fold. From the clinical perspective it means we can discount or treat potential infections in a more timely fashion; for instance, we use RespCheck to screen for any suspected infectious respiratory disease cases which enables us to deal with the problem, through quarantine and strict hygiene measures, helping to prevent the spread of the disease.
The other benefit is to our practice reputation and the standard of service we can offer. It's great to be able to provide owners with peace of mind without it costing more than our call out fee. By the time an owner calls the vet they are usually stressed and worried about their horses symptoms and need some reassurance, which is exactly what RespCheck gives them. We are confident that providing a diagnostic service that is completely free and that puts an owners mind at rest regarding the risk of an infection can only be a good thing for our practice reputation and customer care.
Last year, the service proved its worth when the screening of a recently imported horse showed the animal had equine influenza. I believe that had RespCheck not been employed, we would have had an outbreak in that particular yard."
Practices interested in knowing more about RespCheck should contact their local Intervet/Schering-Plough Veterinary Business Manager or phone the company's Veterinary Support Group on 01908 685685.
New research published in the Equine Veterinary Journal (EVJ) has shown that the use of standing sedation to repair lower limb fractures in racehorses produces similar results to surgery performed under a general anaesthetic, but with the advantages of less surgical complexity, time, cost and risk.
The study Short and long term results following standing fracture repair in 34 horses was conducted by Richard Payne and Polly Compston at Rossdales Equine Hospital1.
Standing fracture repair in the horse is a relatively new surgical procedure with very little follow-up data available. Treatable fractures sustained by racehorses in the UK have traditionally been repaired under general anaesthesia but it is well known that this carries an increased risk of anaesthetic-related death compared with other elective surgical procedures. However, despite the substantial increase in the number and type of surgical procedures performed under standing sedation over the past decade there has previously been very little work undertaken on standing fracture repairs.
The study looked at the case records of 34 Thoroughbred and Arab racehorses that had a lower limb fracture surgically repaired by one surgeon at Rossdales up until June 2011. The injuries included non-displaced fractures of the proximal phalanx, the third metacarpal bone and the third metatarsal bone, all of which are relatively common fracture sites in racehorses. Hospital records, owner and trainer telephone questionnaires and website research were used to evaluate follow-up. The short and long-term results were similar to those of horses undergoing repair of comparable fracture configurations under general anaesthesia, with 20 of the horses returning to racing within an average of 226 days.
This early research indicates potential for tangible benefits, including avoidance of the inherent risks of general anaesthesia as well as a reduction in surgical complexity and associated costs, leading the way for future research into larger cohorts of horses.
EVJ's Editor Celia Marr said: "The recent fatalities at the Grand National highlight that it is critical that the equine veterinary research community strives to reduce the prevalence of fractures in our racehorses. We also need to continue to seek better ways of treating those horses that do develop fractures and, while not every fracture will be amenable to this approach, this study is an important first step towards treating some of the non-displaced fractures that occur in racehorses without the need for anaesthesia."
1Short and long term results following standing fracture repair in 34 horses Richard Payne and Polly Compston, Equine Veterinary Journal ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00569.x
The National Office of Animal Health has completed its annual review of its Code of Practice for the Promotion of Animal Medicines, and a number of changes will come into effect on 1st July 2011.
One change spells out the way antimicrobial medicines are promoted to farmers, with a firm emphasis on correct use and education.
Advertisers will be required to describe the condition the product is aiming to treat, and to promote an understanding of the treatment of the disease.
The phrase "use medicines responsibly" will always be included in text, making the voluntary strapline introduced in 2009 a formal part of the NOAH Code. As with all promotions to people other than prescribers, farmers will always be reminded to consult their veterinary surgeon.
Advertising text will always state clearly the name of the company and the brand being promoted, and promotion must not be designed to disguise its real nature.
Withdrawal periods for products will be stated, but these must not be unduly prominent and not in a font size greater than the body copy containing recommended dosage and species description.
The changes were proposed by NOAH within its formal response to the Veterinary Medicines Directorate's consultation on the Veterinary Medicines Regulation 2010. The Minister decided in December 2010 to continue to allow the advertising of antimicrobial veterinary products to farmers.
Phil Sketchley, NOAH Chief Executive, said: "Whilst welcoming the Government's decision in December not to further restrict the advertising of animal medicines, we feel that the industry should take a proactive role to ensure the system works properly. We believe it is important for farmers, who are legally responsible for the health and welfare of their animals and the food produced from them, to be aware of the medicines that are available to protect the health of their animals, and at the same time we want them to know that these medicines must be prescribed and used responsibly.
"The issue of antimicrobial resistance is one that affects us all. The way to promote best practice is through education by maintaining all lines of communication between farmers, vets, scientists and animal medicine producers.
"Antibiotics are essential for maintaining the health and welfare of all animals, but like any medicine they need to be used responsibly in order to maintain their effectiveness, and their availability for future generations."
BVA President Gudrun Ravetz said: "Veterinary View not only highlights some of the veterinary profession's fantastic work, but complements our joint project with RCVS, Vet Futures, in exploring how the profession can best shape its own future. We hope it will stimulate debate among vets, and the wider community in which we work, about both the big challenges and opportunities that the veterinary profession is facing."
The series includes a number of videos which showcase more recent industry developments:
Stem Cell therapy for the treatment of canine osteoarthritis (VetCell Therapeutics)
Pharmtrax, a mobile device for vets to record work and dispensing on the farm (Henry Schein Animal Health)
Hormone implants as an alternative to castration (Virbac Animal Health)
Practice management support from Zoetis
Preventing an epidemic of equine flu (Merial Animal Health)
The British Equine Veterinary Association (BEVA) has announced that it is reducing the cost of its CPD by 50% this year and making its webinars free to members.
David Mountford, Chief Executive of BEVA said: "Last year we were able to capitalise on some efficiencies in other areas of BEVA operations. We are delighted to be able to hand the resulting benefits directly back to our members across all our CPD programme during 2013."
The Association says its CPD covers a broad range of topics is aimed at busy vets who need to build CPD points, whether new graduates, equine or mixed practitioners. It takes the form of clinical workshops, regional meetings, nursing meetings, webinars and one, two and three day practical courses, held in the UK.
This year's courses include:
For more information, visit http://www.beva.org.uk/news-and-events/beva-courses or ring +44(0)1638 723555 or email info@beva.org.uk.
MSD Animal Health has announced the launch of KBHH Yard Master – a new preventative healthcare and biosecurity app - as part of its ongoing Keeping Britain’s Horses Healthy (KBHH) campaign.
MSD says KBHH Yard Master has been created to link vets and yards where the majority of horses in Britain are kept. It aims to play a key role in protecting the health and welfare of the herd and in safeguarding the yard’s reputation and business.
Peter Young, Equine Business Manager at MSD Animal Health said: "Good biosecurity is essential in building and maintaining the reputation of a yard which, in turn, impacts on owner satisfaction and retention. It remains, however, a poorly understood subject despite its importance. We’ve therefore invested in the creation of KBHH Yard Master to help vets, yard managers, their employees and horse owners focus on preventative health and biosecurity measures; making best practice seem more achievable and easier to implement.
He added: "We were also fortunate to have input from Professor Josh Slater, who has been heavily involved in developing the content, evaluation and grading system behind the app assessment."
KBHH Yard Master covers all aspects of biosecurity, including everyday husbandry practices, managing new arrivals, running isolation facilities, infection control and personnel movement. MSD says it will frame a dialogue with yard managers regarding preventative healthcare and biosecurity in situ and provide instant feedback on current practices and risk. Following the on-site assessment, a report can be sent to the yard manager with tailor-made recommendations and timings, detailing how they can improve their yard’s biosecurity performance.
Peter added: "Based on the data gathered through the KBHH campaign we know that approximately half of horses are vaccinated for ‘flu. This means that there will be horses on yards, visited by vets, that are not vaccinated. KBHH Yard Master will help identify those horses and allow the vet to recommend appropriate vaccination schedules."
MSD has produced a range of supporting KBHH Yard Master materials to promote understanding, participation and compliance amongst yard staff and owners, including posters and downloadable booklets which explain aspects such as disease prevention, infection control and outbreak control.
A certificate of excellence is also available to be awarded to those yards which, following assessment, have a low overall biosecurity risk.
For more information, contact your MSD Animal Health Equine Account Manager or call MSD on 01908 685685.
The webinars each last between three and five minutes and are part of the 2016 ‘Talk About Laminitis’ disease awareness initiative to help detect, manage and monitor PPID.
The webinars can be viewed on the Boehringer Academy website – www.boehringer-academy.co.uk - and podcast versions are also available enabling veterinary professionals to listen to them ‘on the go’.
The first series includes:
The second webinar series covers:
For further information on the webinars or podcasts visit www.boehringer-academy.co.uk or contact your local Boehringer Ingelheim territory manager.
The session will be conducted in the style of the BBC Radio 4 Moral Maze discussion programme, with panelists and witnesses arguing for and against the viewpoint corporatisation is inevitable and will benefit vets and their clients.
Moderated by Madeleine Campbell, Keith Chandler and Karl Holliman will argue for corporatisation and Andrew Harrison and Tim Greet will be against. They will call upon a series of 'witnesses' for detailed questioning before the topic is more broadly debated.
CVS, the UK’s biggest veterinary group now owns more than 410 veterinary practices, of which over 30 are specifically equine or mixed practices.
The latest equine acquisitions include Bell Equine, a one-site Equine Referral Hospital in Kent, in January 2017 and Severn Edge Veterinary Group, a mixed practice with 12 sites in Shropshire, including a six-vet dedicated equine practice, in April 2017.
One line of argument says that the commercial and business advantages of a corporate, together with their scale and diversity, can give veterinary surgeons greater potential for a more flexible career path and advancement within the industry, and a more sustainable working career in equine practice.
On the flip side, there's the removal of any opportunity to buy into ownership, reduced decision-making ability because of adherence to corporate procedures, extra paperwork, longer approval processes and an increased emphasis on the bottom line.
David Mountford, Chief Executive of BEVA said: "The auditorium is usually full to bursting for our Moral Maze sessions because they bring a broader and more engaging dimension to important topics. The statement Corporatisation of equine practices is inevitable and will benefit vets and their clients is bound to generate some stimulating and possibly heated debate."
This year's BEVA Congress will be held at Liverpool Arena Convention Centre, and anyone who registers before 3rd August will receive significantly reduced booking fees.
For more information, visit: www.beva.org.uk.
The Animal Health Trust is appealing to veterinary surgeons and nurses to encourage clients who keep their horses on premises that have been affected by Equine Grass Sickness to sign up to the second year of its nationwide EGS vaccine trial.
Equine Grass Sickness (EGS) occurs predominantly in Europe, with Britain experiencing the highest incidence worldwide. In 2014, 59 cases of EGS were reported through the EGS Surveillance Scheme, but it is likely that this represents only a fraction of cases occurring annually throughout Britain.
Almost all cases of EGS occur in horses with access to grazing. The AHT says there is growing scientific evidence to suggest that the disease may be caused by the bacterium Clostridium botulinum type C, commonly found within soil and capable of producing neurotoxins to which horses are particularly sensitive. EGS occurs when a combination of risk factors trigger the production of these toxins within the horse's intestinal tract, causing damage to the nervous system and paralysis of the gut.
As similar equine diseases such as tetanus and botulism can be prevented by vaccination, it is theoretically possible that a vaccine could prevent EGS. To this end the AHT, in collaboration with the Universities of Edinburgh, Liverpool and Surrey launched the EGS field vaccine trial in 2014 in order to establish whether a vaccine could indeed be effective in reducing the risk of the disease. The trial is funded by a number of sources including Neogen Corporation; Animal Welfare Foundation; Horserace Betting Levy Board; Racing Foundation; Moredun Foundation Equine Grass Sickness Fund; Hong Kong Jockey Club; The British Horse Society and the EB Moller Charitable Trust.
Now entering its second year, the EGS vaccine trial involves enrolled horses and ponies receiving either a course of the C. botulinum type C toxoid vaccine or an inactive placebo, as well as an annual booster. The incidence of EGS is monitored throughout the trial to determine the efficacy of the vaccine, and enrolled horses and ponies are closely monitored through regular follow-ups for the duration of the trial.
With 60% of EGS cases occurring during April - June, the highest risk season for EGS is fast approaching. The AHT is appealing to owners who keep their horses on premises that have had at least one case of EGS in the past three years to enrol their horse in the vaccine trial and provide an invaluable contribution to this pioneering research prior to these high risk months. Veterinary practices with clients who fit this description are asked to help the recruitment process by encouraging suitable cases to sign up to the trial.
Dr Jo Ireland, the AHT's Equine Grass Sickness Research Co-ordinator, said: "We have been delighted with the overwhelmingly positive response to the EGS vaccine trial and many owners have welcomed the chance to be a part of such important research. We don't want any eligible horse owners to miss out on the opportunity to contribute towards a potential breakthrough in the prevention of EGS, so we are encouraging more owners to enrol their horses on the trial this year."
To find out more about the vaccine trial or how clients can enrol horses and ponies, visit the AHT's dedicated EGS website www.equinegrasssickness.co.uk or email equinegrasssickness@aht.org.uk.
Vetoquinol has launched Myo Power, the latest addition to the Equistro Performance range of nutritional supplements.
The company says that Myo Power has been formulated with the performance and convalescent horse in mind, and that it is an excellent source of easily digestible protein enriched with L-Leucine and other key essential amino acids necessary for optimal muscular cell development, specifically via the mitochondria.
Vetoquinol claims the product is extremely beneficial for young horses being prepared for sales, competition horses in training, and the convalescent or older horse following periods of box rest or restricted exercise.
Myo Power is available in 1.2kg and 2.3kg tubs. For further information, please contact your local Vétoquinol Territory Manager.
The new tool is part of a package that also includes posters and SMS texts to support veterinary practices in raising awareness of gastric ulcers to horse owners.
Equine Gastric Ulcer Syndrome (EGUS) is a serious and common condition and any type of horse can be at risk.1 EGUS can have a profound impact on a horse’s condition and performance and can be life threatening in foals. It is a challenging condition to diagnose as the clinical signs are often vague and not always present.1
Gastroscopy is the only method currently available for a definitive diagnosis. Of the two types of disease equine squamous gastric disease is graded on a numeric scale with 1 being the least severe and 4 being the most serious. Equine glandular gastric disease can be very varied in terms of location and type so grading this disease on a score system is no longer recommended. Instead it is now usually described in terms of location, severity and appearance.2
The new tool has been designed to help vets to map the area affected by gastric disease and record the details in an accessible format. This information, together with treatment and management recommendations, can be shared easily with the client. Posters explaining gastric ulceration have been designed to help increase awareness and understanding of EGUS amongst horse owners.
Zoetis says effective treatment usually involves a combination of management and medical treatments. UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.3 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.3,4 One syringe contains enough UlcerGold for a daily dose for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
References
The Arthrex Vet Systems Mobile Lab will be hosting hands-on sessions to help practitioners develop their arthroscopy and joint block skills in its state-of-the-art laboratory.
BEVA President Roger Smith said: “Our practical sessions are always highly popular and the wetlab experience takes things to the next level."
"The ability to practice ultrasound-guided injections at the conference provides the opportunity to hone your skills in ultrasound and enable you to cement to ultrasound-guided injections of tendons and ligaments and joints into your daily practice.
On the Thursday there will be three wetlab taster sessions at three different stations, giving delegates the chance to sharpen their skills with an ultrasound scanner, arthroscope and arthrobox.
Friday’s sessions will be focused on forelimb joint blocks and arthroscopic demonstrations of the needle locations.
The full BEVA Congress programme is now live and super early bird tickets are available until 7th June 2024.
Individual super early bird BEVA members prices are £524 for vets and £144 for vet nurses for all three days (with concessionary available for those in their first three years of graduation or earning less than £25,000).
Day tickets and practice passes are also available.
http://www.bevacongress.org
Vetoquinol, makers of Sedalin (acepromazine), has published a free clipping guide for horse owners.
The company says the launch of the guide has been timed to coincide with the horse clipping season, when owners may be considering sedating horses to make things safer for themselves and their horses.
The guide refers owners to their veterinary surgeon for professional advice if sedation is appropriate.
The company has also produced promotional practice posters: ' Less Stress more Success'
For your poster and accompanying guides, contact your Vetoquinol Territory Manager or Teleservices directly on 01280 825424. You may also wish to put a link to a downloadable version of the guide on your practice website: http://www.vetoquinol.co.uk/clippingguide.pdf
A new study published in Equine Veterinary Journal's (EVJ) in partnership with the American Association of Equine Practitioners, has shown that a wireless, inertial sensor-based system can effectively measure a horse's response to a flexion test.
The authors say that opinions on the value of flexion tests in assessing equine lameness have been divided for many years, but their research should turn what has always been regarded as a subjective process into a wholly objective one.
Flexion tests are used routinely in horses with subtle or imperceptible lameness, to exacerbate the problem and make it apparent to the observer. The test involves applying a short period of pressure to the joints of the limb before re-examination, and evaluating any change in gait. However, flexion tests rely on the ability of the observer to identify and interpret changes in the horse's gait and in that respect these tests are subjective and not necessarily consistent between observers.
The research study was conducted by orthopaedic surgeons based at the University of Glasgow's School of Veterinary Medicine1. A total of 17 healthy adult horses, all in work, were fitted with sensors before being trotted in a straight line. The sensors measured vertical pelvic movement asymmetry for both right and left hind limb strides and the average difference in maximum and minimum pelvic height between right and left hind limb strides. A hind limb was randomly selected for 60 seconds of proximal flexion, after which the horse was trotted for a minimum of 10 strides. Response to the flexion was blindly assessed as negative or positive by an experienced observer.
John Marshall, lecturer in equine surgery at the University of Glasgow, who led the study, said: "A positive response to flexion resulted in significant changes to objective measurements of pelvic symmetry, supporting the use of inertial sensor systems to objectively assess response to flexion tests."
Professor Jim Moore, North American Editor of the EVJ, said: "The introduction of an objective approach to documenting lameness examination will not only help vets and trainers to investigate equine lameness more accurately. It will also serve as an unbiased method of communicating lameness examination findings among vets, trainers, farriers and other professionals."
The next phase of research will be to establish cut-off values for objective assessment of other equine lameness diagnostic procedures, such as nerve blocks.
Reference
The Fédération Équestre Internationale (FEI) has added Metacam for Horses to its 'list of detection times'.
According to the manufacturer, Boehringher Ingelheim Vetmedica, Metacam (meloxicam) is the first preferential COX-2 inhibitor to be added to this list, and has stated plasma and urine detection times of 72 hours administered intravenously or orally1. This is the shortest urine detection time of the NSAIDs available for use in horses, and compares to the 168-hour (7 days) detection time for phenylbutazone stated by the FEI.
Craig Beck, equine sales and marketing manager for Boehringer Ingelheim in the UK and Ireland said: "We have been very happy to work in partnership with the FEI to provide the robust data that has supported the FEI in their analysis of Metacam. Metacam is an important addition to the FEI list, that will help vets treating competition horses. There is now a modern and proven NSAID which extends the therapeutic options available to vets."
Metacam is licensed in horses for the alleviation of inflammation and relief of pain associated with musculo-skeletal disorders or colic.
1 Detection Time agreed with the European Horse Racing Scientific Liaison Committee (EHSLC)
The Veterinary Marketing Association has announced details of a new award for public relations, open to veterinary practices and companies.
The VMA says this award is to recognise the value that media and public relations can add to the marketing mix. It will be awarded to the company or veterinary practice that has delivered the most innovative PR campaign during 2011, as judged by a panel of industry professionals.
Organiser Claire Edmunds said: "The VMA Awards has become a coveted event for those involved in the animal health industry to showcase their marketing achievements. A range of categories has evolved since the awards began over 20 years ago, for marketing, creative communication and new media campaigns. However, we felt that an award for PR was required to complete the marketing mix".
Jane Manning from award sponsor Splash Marketing & Communications said: "We felt it was time to give the opportunity for those involved in PR to obtain the recognition they deserve alongside their creative colleagues.
"An effective PR campaign can be a highly influential marketing tool, so it's great news that the VMA has added this new award category. We hope that companies and agencies serving the animal health sector will embrace this new opportunity to showcase their creativity and hard work".
The award is for the most innovative PR initiative published during the year. This can be a single 'one-off' event or article, or a sustained campaign over a given period. The winner and two highly commended entries will be awarded at the VMA Awards on Friday 9th March 2012 at Shakespeare's UnderGlobe Theatre, London.
Further information on the awards and ticket application forms are available at the VMA's website - http://www.vma.org.uk/ or by calling 0844 561 6157. The deadline for entries is Friday 27th January 2012.
VetCell Bioscience has become the first UK-based stem cell centre to be authorised under the Veterinary Medicines Regulations.
Following a rigorous series of inspections and reports by Good Manufacturing Practice (GMP) Inspectors VetCell, in conjunction with their UK laboratory partner Biobest, were officially authorised as an equine stem cell centre on 1 October 2009.
David Mountford, Chief Operating Officer of VetCell Bioscience said: "To have received formal authorisation so swiftly reflects the high standard of our operation and our ability to lead the field in the increasingly competitive sector of stem cell technology."
Stem cell therapy involves implanting millions of the animal's own stem cells and autologous growth factors directly into the injured tendon or ligament. The service VetCell Bioscience offers is the collection, storage, processing and supply of stem cells suitable for administration back into the donor animal.
According to the company, there is considerable interest from the human sector and studies in human medicine, for the treatment of Achilles tendinopathies, could begin as early as next year.
The UK's first online gastric ulcer risk assessment for horse owners has just been launched as part of the 2009 Gastric Ulcer Awareness Month (GUAM), organised by Merial Equine Health.
Merial has developed the risk online questionnaire to enable owners to evaluate their horse's risk of ulcers. By logging on to the website http://www.gastriculcerrisk.co.uk/, owners, trainers and riders can complete a form which then returns the results via email. Where an animal is considered to be at medium to high risk, owners will be advised to consult their veterinary practice.
The company's Dr Emma Batson said: "Since the first GUAM in 2007, significant progress has been made in developing awareness and understanding of equine gastric ulcer syndrome.
"However there is still more to do! Our goal is to move gastric ulcers further up the diagnostic process, such that the condition is an early consideration for all horses presented with the vague symptoms associated with ulceration. We know that due to the vague nature of the symptoms, many of horses are suspected of other ailments such as back and teeth problems, general poor performance, or behavioural issues prior to being diagnosed with ulcers.
"This new initiative has been developed through consultation with practising internal medicine specialists. We hope it will help to highlight more cases and encourage clients into the practice with horses that are at genuine risk of ulcers. Further diagnosis, treatment and management measures can then be considered in consultation with the client.
"The website also has a veterinary page so that follow up information and any gastroscopy results can be recorded by the vet. We hope that this feedback will help generate some valuable data for the industry."
To help you promote this initiative, Merial has produced an impactful poster for use in practice waiting rooms, along with educational literature. The poster will be available as a loose insert in various publications during April and May.
For those practices which require a referral scoping service, Merial can put you in touch with three specialist consultants; Rachael Conwell (North) Dr.Tim Brazil (Midlands/nationwide) and Richard Hepburn (South West) who each provide a mobile scoping clinic.
Merial is also promising support for the mobile scoping service for the five practices that direct the largest number of clients to http://www.gastriculcerrisk.co.uk/
A number of events are also taking place during the month for vets, trainers and horse owners, including the following CPD events:
GUAM is supported by BEVA and Dr Batson hopes that the 2009 initiatives will further boost awareness, understanding and diagnosis of this underrated condition.
New research from the USA, published in the Equine Veterinary Journal (EVJ), has shown that a toxin from the box elder tree is the likely cause of Seasonal Pasture Myopathy (SPM), the US equivalent of the European disease known as Atypical Myopathy (AM).
According to the British Equine Veterinary Association, preliminary comparisons of these results with cases of AM in Europe suggest that the European condition may be linked to similar trees which could have an important bearing on the future prevention of the disease in Europe.
Seasonal Pasture Myopathy is a highly fatal muscle disease in Midwestern USA and Eastern Canada. A similar disorder called Atypical Myopathy is becoming increasingly frequent in the UK and Northern Europe. Outbreaks of both diseases tend to be seasonal, with most cases occurring in the autumn. Horses that develop SPM and AM are usually kept in sparse pastures with an accumulation of dead leaves dead wood and trees in or around the pasture and are often not fed any supplementary hay or feed.
The research1 identified that seeds from box elder trees were consistently present in the autumn pastures of all 12 horses enrolled in the study. These horses were from 11 different farms and had all presented with the clinical signs of SPM, which include muscular weakness and stiffness, dark urine, periods of recumbency, colic-like signs and muscle trembling. The toxic amino acid hypoglycin A, which is known to cause acquired multiple acyl CoA dehydrogenase deficiency (MADD) was shown to be present in the box elder seeds and hypoglycin metabolites were identified in the serum or urine of all the horses. All but one of the cases proved fatal.
Professor Valberg DVM PhD of the Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, who instigated the study, said: "The fact that another acquired form of MADD in rats and humans is caused by hypoglycin A ingestion strengthens our conclusion that hypoglycin A is the likely toxic cause of SPM in horses. We are intending to conduct further studies to determine the factors that affect the highly variable hypoglycin A concentrations in box elder seeds."
Professor Valberg has established collaborative links with groups in Europe in order to investigate if a similar toxin is involved in European Atypical Myopathy. Working with Professor Vince Gerber and Dr Lucia Unger at the University of Bern, Professor Valberg has obtained seeds from a tree related to the Box Elder found on many pastures where Atypical Myopathy has occurred.
Professor Celia Marr, Editor of Equine Veterinary Journal said: "This is a really important step forwards. We don't yet know for sure that the cause of European disease, Atypical Myopathy, is the same as Seasonal Pasture Myopathy in the US. But the clinical signs and MADD aberrations are identical and both conditions have a high fatality rate. It remains to be seen whether this research will help European horses, but there is no doubt that it will allow American horse owners to prevent this devastating condition affecting their horses with immediate effect."
1 Seasonal Pasture Myopathy/Atypical Myopathy in North America associated with Ingestion of Hypoglycin A within Seeds of the Box Elder Tree Stephanie J Valberg DVM PhD1, Beatrice T Sponseller Dr. med. vet2, Adrian D Hegeman PhD3, Jennifer Earing PhD, Jeffery B. Bender DVM MS1, Krishona L Martinson PhD4, Steven E Patterson PhD5, Lawrence Sweetman PhD1
The recommendation follows the analysis of data collected as part of the company's Talk About Laminitis disease awareness initiative, which has seen more than 47,000 horses tested for PPID since it was launched in 20121.
The data revealed that, regardless of presenting clinical signs, a horse aged 15-20 is three times more likely to have PPID compared to a horse under 10, and this risk increases with age. For example, a horse of 20-25 is six times more likely to have PPID compared to a horse under 10 and a horse that is 25-30 is 10 times more likely to have PPID.
Boehringer says that despite the high prevalence of PPID in the older horse population, the clinical signs of the disease are insidious in onset and owners may simply associate them with the ageing process.
One study demonstrated that in a single population of horses over the age of 15 only 1.6% of owners reported signs of PPID2. However, when the same group of horses were examined by a veterinary surgeon, 21% were found to have signs of the disease.
Dr Jo Ireland, veterinary surgeon at the University of Liverpool, said: "It is often difficult for owners to spot the signs of PPID as they frequently associate them with the ageing process. However, PPID is now the fifth most commonly diagnosed disease in horses in the UK3.
"We are therefore encouraging veterinary surgeons to routinely test horses over 15 years of age or those that are displaying signs of PPID with an ACTH test."
The 'Talk About Laminitis' disease awareness initiative runs from June until the end of October and aims to raise awareness of the underlying hormonal causes of laminitis – PPID and Equine Metabolic Syndrome (EMS). As part of the scheme, the laboratory fees for the blood test which detects PPID (the basal ACTH test) are free.
Redwings’ head of veterinary and care, senior veterinary surgeon Nicky Jarvis, said: "Any initiative that decreases the incidence of laminitis developing in an older equine is invaluable. Laminitis is an extremely distressing condition for both the horse and the owner and the long-term consequences can be devastating. Knowing the underlying cause is a huge help in tackling the disease and we would encourage anyone to take advantage of this offer and get their veteran checked out."
For further information about 'Talk About Laminitis', visit www.talkaboutlaminitis.co.uk or contact your local Boehringer Ingelheim account manager.